PARIS - Luc Montagnier, whose group here at the Institut Pasteur first isolated the AIDS virus in 1983 teamed up with an American businessman to create a new research institute in cellular and molecular biology at Queens College in Flushing, New York. Although the main focus of the center will be AIDS research, it will also focus on other chronic human diseases.
Until this month, Montagnier has served as head of the high-powered research department and AIDS retrovirus Pasteur. He plans to maintain its own laboratory unit and stay involved in two organizations based in Paris, he co-founded :. The World Foundation for AIDS Research and Prevention and Research Center Luc Montagnier AIDS
Montagnier was attracted by Queens College graduate Bernard Salick, former head of a network of cancer treatment centers in the USA. In addition to a donation of $ 4.5 million of his own money to start the institute, the Queens Salick responsible and will try to raise some $ 15 million of the State of New York and an additional $ 15 million from private sources . "The prospects are very good," said the spokesman Ron Cannava Queens "because Salick has great contacts with the pharmaceutical industry." Montagnier's plans were reported in The New York Times .
the center will hire five top scientists as professors at Queens College. Montagnier said Science now that the AIDS research center will focus on developing a vaccine against AIDS and to find therapies "which relieve patients from having to deal every day for the rest of their lives." While some researchers may accompany Pasteur, Montagnier said the new institute "will mostly an American center, led by Americans. "Montagnier adds that he began to probe some American scientists about upcoming Queens, but he refuses to identify.
the center will take about two years to build, but Montagnier said that he is eager to begin working in the temporary laboratory space in college. One main reason to jump on the Atlantic, Montagnier said, is that discoveries in the US can be exploited much more quickly than in France: "There is a greater potential for results applied by the industry. and biotech companies "
0 Komentar